Vaccibody Becomes Nykode Therapeutics - a New Name and Identity to Signify a New Phase of Growth and Development
Nykode Therapeutics (formerly Vaccibody*)) (Euronext Growth (Oslo): VACC (ticker will soon be changed)), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today that the Company is changing its name to reflect its exciting development and mark a milestone in our journey of growth and transformation. It acts as a visible symbol of a new phase of opportunity based on collaborations, internationalization, and future ambitions. And it conveys how we are truly starting to realize our vision of being a leading immunotherapy platform company, breaking down the boundaries of conventional drug design to unlock the future of medicine.
The Company’s new name is inspired by its Norwegian roots and links to our platform’s modularity. Nykode translates as ‘new code’, playing on the potential of our technology to generate novel codes and create innovative patient therapies.
Michael Engsig, CEO of Nykode Therapeutics: “Over the last few years, the Company has made significant steps forward. We have reported promising clinical data, continued to grow our pipeline and forged significant partnerships.” Michael Engsig added, “We continue our exciting transformation from a two-asset focused company to a fully-fledged platform biotech company. During the past year, we have increased the number of talented colleagues, made important additions to our senior management team, invested strategically, and expanded internationally. This positive evolution, combined with our future ambitions, inspired the need to revisit our brand.”
Agnete B. Fredriksen, Chief Innovation & Strategy Officer of Nykode Therapeutics, continued, “The challenge of changing our name was to consolidate everything we have achieved to date with our future plans to expand, and combine this into a powerful new brand.” Agnete B. Fredriksen added, “We have shown that we can generate novel molecules by combining multiple different genes or codes to generate new medicines with unique properties. We will build further on this know-how, driven by our guiding purpose to push the boundaries of human advancement by rethinking conventional drug design. We want to express how our platform’s intelligent modular design and tailored hyper targeting may deliver game-changing medicines for patients. This vision aims to create innovative therapies and continues to broaden our reach into multiple therapeutic areas, both with and without our partners. In essence, we believe that our new name, Nykode, uniquely captures our progress and possibilities.”
Read more about the journey and inspiration regarding our new name, logo, and visual identity on our new website, nykode.com.
*) Vaccibody AS, which is changing its company name to Nykode Therapeutics AS, has called for an EGM on November 30, 2021, to vote for the approval of the change of its company name from Vaccibody AS to Nykode Therapeutics AS.
About Nykode Therapeutics
Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment cancer and infectious diseases. Nykode Therapeutics’ modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses.
Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumours and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode Therapeutics has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.
The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and collaborate with Adaptive Biotechnologies for COVID-19 T cell vaccine development.
Nykode Therapeutics’ shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC (ticker will soon be changed). Further information about Nykode Therapeutics may be found at http://www.nykode.com
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006744/en/
Contact information
Contact for Nykode Therapeutics AS:
CEO Michael Engsig
Nykode Therapeutics AS
ir@nykode.com
Nykode Therapeutics AS
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SS&C Expands European Wealth Management Capabilities with New MiFID License in Ireland25.11.2025 14:00:00 EET | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced significant expansion of its European wealth management business with the establishment of SS&C Wealth Services Europe Ltd. The business has been granted authorization under the Markets in Financial Instruments Directive (MiFID) by the Central Bank of Ireland. The license strengthens SS&C’s ability to serve the European Union’s wealth management sector. The company can now deliver its full suite of technology-enabled wealth management solutions directly from Ireland. The new operation builds on SS&C’s successful U.K. wealth management business, creating a pan-European platform with advanced technology, deep regulatory expertise, and comprehensive servicing capabilities. Based in Dublin, the business will focus on helping financial institutions modernize and scale their wealth operations through SS&C’s integrated wealth platform, custody, and back-office services. SS&C employs more than 550 professionals in Ireland, servici
A-HEAT Allied Heat Exchange Technology AG mourns CEO Christian Weiser25.11.2025 14:00:00 EET | Press release
With deep sorrow, A-HEAT/Güntner announces the sudden and unexpected passing of Christian Weiser, CEO of A-HEAT Allied Heat Exchange Technology AG (A-HEAT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125106542/en/ Christian Weiser “We have lost a truly remarkable person. Christian Weiser was a leader of integrity, empathy, and humor. His tireless commitment helped to make the A-HEAT Group what it is today,” said Hubert Spegel, Member of the Board at A-HEAT. “Our thoughts and deepest sympathy go to his family, his loved ones, and all those who worked with him. We will honor his legacy and strive to continue his work with the same passion and conviction.” Throughout his decades-long career within the group, Christian Weiser held numerous leadership positions before being appointed CEO of A-HEAT. Under his leadership, the A-HEAT/Güntner Group expanded its global presence, strengthened its innovation and sustainability in
HCLTech Signs Strategic Collaboration Agreement With AWS to Accelerate Financial Services Industry Transformation With AI and Core Modernization25.11.2025 12:30:00 EET | Press release
HCLTech, a leading global technology company, today announced that it has signed a strategic collaboration agreement with Amazon Web Services (AWS) to accelerate innovation in the financial services industry through autonomous, AI-powered solutions. The collaboration brings together HCLTech’s deep domain expertise and AWS to deliver transformative outcomes for financial services organizations. “We understand that a digital journey is of strategic importance and the need of the hour is for a trusted partner that can engage across the transformation lifecycle,” said Srinivasan Seshadri, Chief Growth Officer and Global Head of Financial Services at HCLTech. “Financial institutions face increasing pressure to modernize their systems, deliver exceptional customer experiences, and meet sustainability requirements and many struggle with legacy infrastructure, siloed data, and complex regulatory requirements. Our collaboration with AWS addresses these challenges by providing proven solutions a
Bridgepoint to Partner With ht.digital, the Leading Digital Asset Transparency Layer25.11.2025 10:00:00 EET | Press release
Bridgepoint, one of the world’s leading mid-market investors, today announced that it has agreed to acquire a majority stake in ht.digital, a leading, London-headquartered provider of digital asset assurance and technology solutions. The investment will be made by Bridgepoint Development Capital V – Bridgepoint’s lower middle-market fund focused on supporting fast-growing businesses across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125907148/en/ Digital assets – including cryptocurrencies, stablecoins and tokenised financial instruments, all built upon blockchain technology – are an increasingly important part of the global financial system. As adoption accelerates, regulation is driving vast demand for independent, institutional-grade assurance services to strengthen transparency and safeguard investors. ht.digital is the leading digital asset transparency layer. From proof of reserves and attestations to fin
Thredd Signs Landmark Agreement to Enable Visa Cloud Connect Globally25.11.2025 10:00:00 EET | Press release
Thredd, a leading next-generation global payments processor, today announced that it has signed an agreement to enable Visa Cloud Connect on a global scale. This milestone reflects Thredd’s continued investment in cloud-first infrastructure and reinforces its role as a global technology leader in payments processing. Visa Cloud Connect allows organisations to access VisaNet, Visa’s secure and powerful global payments network, through their own cloud-based infrastructure. Purpose-built for cloud-native clients, Visa Cloud Connect can help deliver increased flexibility, faster time to market, and seamless scalability across borders. Under the agreement, Thredd will connect across three global Visa Cloud Connect endpoints, committing to a full global rollout. Once live, this will eliminate the need for multiple regional integrations, helping our clients gain new geographies and accelerating Thredd’s vision of a unified global processing platform. "Signing this agreement is about future-pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom